Loading…
Diversified health care company combining a diagnostics lab (BioReference), a pharmaceutical pipeline and specialty products.
Diversified health care company combining a diagnostics lab (BioReference), a pharmaceutical pipeline and specialty products.
Collects royalties and milestone payments from partners that sell its drugs, notably Pfizer for the growth hormone Ngenla (somatrogon), while selling Rayaldee itself. Phillip Frost, the chairman, is the largest shareholder.
Moat: none (scale). Diversified but sub-scale mix of lab testing and pharma assets lacks a clear single competitive advantage.
Headquarters: Miami, Florida · Employees: 2,275
Size OPKO Health (OPK) is a United States Health Care company (Medical/Nursing Services) with a market value of $1.29B, the 2088th largest of 3,117 United States companies the cockpit tracks. Shares closed at $1.73 on 6 Nov 2026.
Performance Over six months the shares gained 51.8%, against +20.6% for the median peer and -1.1% for the United States market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue fell 11.5% over the last twelve months (peer median +7.9%); the operating margin is -28.6% (peer median 6.2%).
Valuation It trades at 2.4× enterprise value to sales against a peer median of 2.0× (9th most expensive of 21).
Capital Return on invested capital runs 21.1 points below its cost of capital (10.8% WACC).
Credit OPKO Health has 1 bond outstanding ($121M).
Short interest Short interest is 4.6% of the free float (15 Oct 2026).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $588M | $607M | $713M | $863M | $1.00B |
| Revenue growth | — | -15% | -17% | -14% | — |
| Gross profit | $163M | $128M | $136M | $232M | $204M |
| EBITDA | -$78.2M | -$127M | -$175M | -$52.8M | -$137M |
| Net income | -$72.9M | -$226M | -$53.2M | -$189M | -$328M |
| Free cash flow | -$134M | -$191M | -$208M | -$44.5M | -$120M |
| Capital expenditure | $10.6M | $12.3M | $25.0M | $16.3M | $24.6M |
| Total debt | $398M | $397M | $504M | $327M | $306M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| OPKO Health OPK | $1.29B | +52% | -11% | -29% | 2.4× | n/a |
| Labcorp LH | $29.8B | +45% | +6% | 11% | 2.5× | 13.9% |
| Quest Diagnostics DGX | $28.1B | +36% | +9% | 15% | 2.9× | 6.4% |
| Pfizer PFE | $168B | +14% | +1% | 26% | 3.4× | -4.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | OPK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +26.3% | +4.8% | 3rd highest of 21 |
| 6-month return | +51.8% | +20.6% | 4th highest of 21 |
| Distance from 52-week high | -7.0% | -17.1% | 5th highest of 21 |
| Revenue growth (TTM) | -11.5% | +7.9% | 2nd lowest of 21 |
| Operating margin | -28.6% | 6.2% | 2nd lowest of 21 |
| EV / Sales | 2.4× | 2.0× | 9th most expensive of 21 |
| ROIC minus cost of capital | -21.1 pp | -3.1 pp | 2nd lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| OPKO Health OPK | United States | $1.29B | +52% | -11% | -29% | 2.4× | n/a | n/a |
| Diagnostyka DIA.WA | Poland | $1.29B | -5% | +19% | 15% | 2.4× | 6.9% | +18.9% |
| Lumexa Imaging LMRI | United States | $1.29B | +29% | +8% | 3% | 2.1× | n/a | n/a |
| Pennant PNTG | United States | $1.27B | +1% | +38% | 6% | 1.6× | 21.1% | +19.4% |
| Metropolis Healthcare METROPOLIS.NS | India | $1.25B | +12% | +20% | 18% | 6.6× | 32.4% | +10.5% |
| Nutex Health NUTX | United States | $1.24B | +32% | +7% | 43% | 1.8× | -19.5% | +253.5% |
| H.U.Group 4544.T | Japan | $1.35B | +24% | +1% | 2% | 0.9× | 10.1% | +2.1% |
| GoodRx GDRX | United States | $1.20B | +20% | -2% | 12% | 1.8× | 6.8% | +7.7% |
| Clariane CLARI.PA | France | $1.40B | -20% | +1% | 6% | 1.6× | 6.7% | +6.5% |
| Novogene 688315.SS | China | $1.16B | +31% | +6% | 7% | 2.6× | 17.1% | +8.2% |
| U.S. Physical Therapy USPH | United States | $1.48B | +68% | +11% | 10% | 2.7× | 19.9% | +13.0% |
| Sonida Senior Living SNDA | United States | $1.58B | -14% | +49% | -11% | 5.9× | n/a | n/a |
| Regis Healthcare REG.AX | Australia | $1.05B | -17% | +17% | 4% | 1.0× | 14.6% | +14.4% |
| Teladoc Health TDOC | United States | $1.60B | +21% | -2% | -5% | 0.7× | -5.2% | +18.3% |
| Vijaya Diagnostic Centre VIJAYA.NS | India | $1.60B | +22% | +24% | 32% | 16.8× | 39.3% | +16.7% |
| Ambea AMBEA.ST | Sweden | $1.63B | +30% | +13% | 8% | 1.7× | 1.7% | +7.7% |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.63B | -47% | +8% | 3% | 0.7× | 15.0% | -5.1% |
| AdaptHealth AHCO | United States | $1.00B | +8% | -3% | 3% | 0.9× | 16.3% | +25.2% |
| Personalis PSNL | United States | $1.71B | +164% | -13% | -164% | 22.1× | n/a | n/a |
| Azenta AZTA | United States | $1.72B | +104% | +1% | -3% | 2.4× | 56.0% | +8.9% |
| Dr. Agarwal's Health Care AGARWALEYE.NS | India | $1.74B | +15% | +22% | 15% | 7.4× | 41.9% | +26.9% |
OPKO Health has 1 bond outstanding with $121M face value.